(2 mg + 0.05 mg + 4 mg)/ml, liquid for the skin
Prednisolone + Estradiol benzoate + Salicylic acid
Alpicort E and Alpicort F are different trade names for the same drug.
Alpicort E is a liquid for the skin, containing prednisolone, female sex hormones, and salicylic acid for use on the scalp.
Indications: in the course of various forms of alopecia, especially androgen-dependent alopecia.
Before starting to use Alpicort E, you should consult a doctor or pharmacist.
Alpicort E may be used only externally on the scalp due to its isopropyl alcohol content.
When treating for more than 2-3 weeks, due to the estrogen content in the solution, special precautions should be taken:
Protect your eyes and mucous membranes from contact with the medicine.
If the patient experiences blurred vision or other vision disturbances, they should contact their doctor.
Alpicort E may enhance the effect of other externally used active substances due to its composition.
You should tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
Pregnancy
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before using this medicine. During pregnancy, Alpicort E should not be used due to its salicylic acid content, except when used on small areas (surface area less than 5 cm).
Alpicort E should not be used due to its estrogen content.
If you become pregnant during treatment, you should stop using Alpicort E immediately. However, previous studies have not shown any effect on subsequent fertility due to exposure to estrogen. During long-term treatment with glucocorticoids - a component of Alpicort E - during pregnancy, growth disturbances and harm to the unborn child cannot be excluded.
Breastfeeding
Your doctor should consider that prednisolone passes into breast milk.
The doctor will carefully assess whether it is necessary to use Alpicort E during breastfeeding. If long-term treatment is necessary, you should stop breastfeeding.
During breastfeeding, estrogens may change the amount and composition of human milk. Small amounts of estrogens or their metabolites may pass into the milk of breastfeeding women and affect the child. Glucocorticoids also pass into human milk. Therefore, during treatment with Alpicort E, you should not breastfeed, or you should start treatment with Alpicort E only after the end of the breastfeeding period.
Alpicort E does not affect the ability to drive vehicles or operate machines.
The medicine contains 50 mg of propylene glycol in 1 ml of solution (which approximately corresponds to 180 mg of propylene glycol in a single application). Propylene glycol may cause skin irritation.
This medicine should always be used according to the doctor's recommendations. In case of doubts, you should consult a doctor or pharmacist.
Alpicort E should always be used according to the doctor's recommendations and the instructions in this leaflet. In case of doubts, you should contact your doctor again.
Alpicort E is a solution for use on the skin.
If the doctor does not recommend otherwise, Alpicort E should be used once a day, preferably in the evening.
Once the inflammatory symptoms have subsided, it is sufficient to use 2 to 3 times a week.
During each use, proceed as follows:
The treatment duration for small areas should not be longer than 2-3 weeks due to the presence of prednisolone in the solution. Clinical experience includes a treatment period of up to 6 months. No studies have been conducted on the duration of the effect after stopping the medicine.
In case of using a higher dose of Alpicort E than recommended, you should immediately consult a doctor or pharmacist.
You should not take a double dose to make up for a missed dose.
You should continue treatment by taking the next planned dose at the usual time.
You should discuss further action with your doctor, as the effectiveness of the treatment is at risk.
In case of any further doubts about using this medicine, you should consult a doctor or pharmacist.
Like all medicines, Alpicort E can cause side effects, although not everybody gets them.
Rarely(may occur in less than 1 in 1,000 people): skin hypersensitivity (allergic contact dermatitis)
Very rarely(may occur in less than 1 in 10,000 people): as with the use of any corticosteroid preparations, long-term use may lead to skin changes (reduction of skin thickness, widening of small blood vessels, formation of striae, steroid acne, perioral inflammatory skin disease, excessive body hair).
Unknown(frequency cannot be estimated from the available data): blurred vision
Additionally, short-term skin irritations (e.g., burning, redness) are possible.
During long-term use in high doses or on large areas, as well as in cases of use not in accordance with the intended use, systemic corticosteroid effects are possible.
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181 C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, you can help gather more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Store in a temperature below 30°C. Store in the original packaging to protect from light. Do not freeze.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste containers.
You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Alpicort E is a clear, colorless solution. The packaging contains a brown glass bottle with an applicator and a polypropylene closure, containing 100 ml of the medicine, and a leaflet.
For more detailed information, you should contact the marketing authorization holder or the parallel importer.
Dr. August Wolff GmbH & Co. KG Arzneimittel
Sudbrackstrasse 56
33611 Bielefeld
Germany
Dr. August Wolff GmbH & Co. KG Arzneimittel
Sudbrackstrasse 56
33611 Bielefeld
Germany
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in the Czech Republic, the country of export:46/151/94-C
Parallel import authorization number:175/13
Date of leaflet approval: 03.02.2023
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.